Patents by Inventor Casey T. Weaver

Casey T. Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9017685
    Abstract: The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4+ T cell lineage with unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a basis for understanding the developmental pathway of Th-17 cells and offer novel avenues to modulate (stimulate or inhibit) this developmental program and offer new methods for the treatment and prevention of disease states and conditions related to aberrant activity of Th-17 cells.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 28, 2015
    Assignee: The UAB Research Foundation
    Inventors: Casey T. Weaver, Paul R. Mangan, Laurie E. Harrington
  • Patent number: 8414897
    Abstract: The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4+ T cell lineage with unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a basis for understanding the developmental pathway of Th-17 cells and offer novel avenues to modulate (stimulate or inhibit) this developmental program and offer new methods for the treatment and prevention of disease states and conditions related to aberrant activity of Th-17 cells.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: April 9, 2013
    Assignee: The UAB Research Foundation
    Inventors: Casey T. Weaver, Paul R. Mangan, Laurie E. Harrington
  • Publication number: 20100203009
    Abstract: The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4+ T cell lineage with unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a basis for understanding the developmental pathway of Th-17 cells and offer novel avenues to modulate (stimulate or inhibit) this developmental program and offer new methods for the treatment and prevention of disease states and conditions related to aberrant activity of Th-17 cells.
    Type: Application
    Filed: October 16, 2009
    Publication date: August 12, 2010
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Casey T. Weaver, Paul R. Mangan, Laurie E. Harrington